Day: June 6, 2022

Delta 9 Announces Overnight Marketed Public Offering of Units for $2 Million

Delta 9 Announces Overnight Marketed Public Offering of Units for $2 Million

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES WINNIPEG, Manitoba, June 06, 2022 (GLOBE NEWSWIRE) — Delta 9 Cannabis Inc. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the “Company”) is pleased to announce that it has entered into an agreement with Research Capital Corporation as sole agent and sole bookrunner (the “Agent”), in connection with an overnight marketed public offering of units of the Company (the “Units”) at an indicative price of $0.22 per Unit, priced in the context of the market, for gross proceeds of approximately $2,000,000 (the “Offering”). Each Unit shall be comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant of the Company (a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one Common...

Continue reading

Hanover Bancorp, Inc. Announces Closing on Overallotment Option and Issuance of 191,250 Shares of Common Stock

Hanover Bancorp, Inc. Announces Closing on Overallotment Option and Issuance of 191,250 Shares of Common Stock

MINEOLA, N.Y., June 06, 2022 (GLOBE NEWSWIRE) — Hanover Bancorp, Inc. (Nasdaq: HNVR) (the “Company”), parent company of Hanover Community Bank, today announced that the underwriters for its recently completed initial public offering had exercised their overallotment option to purchase an additional 191,250 shares of its common stock at a public offering price of $21.00 per share. The exercise of the overallotment option and the issuance of the additional shares is expected to result in gross additional proceeds to the Company of approximately $4.0 million. The net proceeds to the Company, after deducting the underwriting discount and estimated additional offering expenses, are expected to be approximately $3.8 million. A registration statement relating to these securities has been filed with the U.S. Securities and...

Continue reading

Microchip Technology to Present at the Stifel Cross-Sector Insight Conference

Microchip Technology to Present at the Stifel Cross-Sector Insight Conference

CHANDLER, Ariz., June 06, 2022 (GLOBE NEWSWIRE) — (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected and secure embedded control solutions, announced today that the Company will present at the Stifel Cross-Sector Insight Conference on Tuesday, June 7 at 11:30 a.m. (Eastern Time). Presenting for the Company will be Mr. Steve Sanghi, Executive Chair. A live webcast of the presentation will be made available by Stifel, and can be accessed on the Microchip website at www.microchip.com. Any forward looking statements made during the presentation are qualified in their entirety by the discussion of risks set forth in the Company’s Securities and Exchange Commission filings. Copies of SEC filings can be obtained for free at the SEC’s website (www.sec.gov) or from commercial document retrieval...

Continue reading

Microchip Technology to Present at the Bank of America Securities 2022 Global Technology Conference

Microchip Technology to Present at the Bank of America Securities 2022 Global Technology Conference

CHANDLER, Ariz., June 06, 2022 (GLOBE NEWSWIRE) — (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected and secure embedded control solutions, announced today that the Company will present at the Bank of America Securities 2022 Global Technology Conference on Wednesday, June 8 at 12:45 p.m. (Pacific Time). Presenting for the Company will be Mr. Ganesh Moorthy, President and CEO, and Mr. Eric Bjornholt, Senior Vice President and CFO. A live webcast of the presentation will be made available by BofA, and can be accessed on the Microchip website at www.microchip.com. Any forward looking statements made during the presentation are qualified in their entirety by the discussion of risks set forth in the Company’s Securities and Exchange Commission filings. Copies of SEC filings can be obtained...

Continue reading

SmileDirectClub Appoints Troy Crawford as Chief Financial Officer

SmileDirectClub Appoints Troy Crawford as Chief Financial Officer

Proven In-House Executive Positioned To Advance Strategic Growth Initiatives For Profitability NASHVILLE, Tenn., June 06, 2022 (GLOBE NEWSWIRE) — SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the first medtech platform for teeth straightening, today announced the appointment of Troy Crawford as its Chief Financial Officer, effective June 6, 2022. Mr. Crawford has served as the interim CFO since January 8, 2022. Mr. Crawford joined the Company as Chief Accounting Officer in January 2020. In his role as CFO, he will continue to report directly to CEO and Chairman, David Katzman, serving as a strategic advisor and responsible for accounting, treasury, tax, FP&A, capital planning and deployment, and investor relations. “Since stepping into the interim CFO role at the start of the year, I’ve had...

Continue reading

Duke Realty Announces Participation in  NAREIT’s REITweek: 2022 Investor Conference

Duke Realty Announces Participation in NAREIT’s REITweek: 2022 Investor Conference

INDIANAPOLIS, June 06, 2022 (GLOBE NEWSWIRE) — Duke Realty Corporation (NYSE: DRE and the “company”), a leader in sustainable industrial real estate development and the largest domestic-only logistics REIT (Real Estate Investment Trust), announced today its management will attend NAREIT’s REITweek: 2022 Virtual Investor Conference being held June 7th to 9th, 2022. Management will deliver a webcast presentation on Wednesday, June 8th from 2:15 p.m. to 2:45 p.m. Eastern Time. To access the live webcast, please use the following link: https://video.ibm.com/embed/24616621. A revised investor presentation file will also be posted on Tuesday morning, June 7th, to the investor relations section of the Duke Realty website at www.dukerealty.com. About Duke Realty Corporation Duke Realty Corporation owns and operates approximately 166.5...

Continue reading

Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting

Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting

Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response and 100% Disease Control Rate. Median progression free survival currently is 22.4 months with all patients still alive as of last follow-up   FOCUS trial update presented with maturing results consistent with earlier presentations Abstract published reporting on a retrospective analysis in the change of Quality of Life in PHP treated patients at the University of Southampton NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced further details regarding presentations relating to its...

Continue reading

K92 Mining Appoints Christopher Kinver as Project Director, Kora Expansion at Kainantu Gold Mine

K92 Mining Appoints Christopher Kinver as Project Director, Kora Expansion at Kainantu Gold Mine

VANCOUVER, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce the appointment of Christopher Kinver as Project Director, Kora Expansion. Mr. Kinver will lead the team that is responsible for the delivery of the Stage 2A and Stage 3 Expansions of the Kainantu Mine. Mr. Kinver joined K92 in September 2019, developing a strong knowledge of the Kainantu Gold Mine and operating in Papua New Guinea, initially as Kainantu’s Mining Manager and most recently the Evaluations and Studies Manager. Mr. Kinver is a Mining Engineer with approximately 20 years of experience in the mining industry, predominantly in senior management roles in underground operations and mine development with senior, intermediate and junior mining companies in Australia, Papua...

Continue reading

Richardson Electronics Sets New Quarterly Sales Record Since 2011

Richardson Electronics Sets New Quarterly Sales Record Since 2011

Preliminary FY22 fourth quarter net sales expected to increase 19.9%-23.8% year-over-year to $60.5 – $62.5 million; total backlog increases to $206.2 million LAFOX, Ill., June 06, 2022 (GLOBE NEWSWIRE) — Richardson Electronics, Ltd. (NASDAQ: RELL) today announced preliminary net sales and backlog results for its fourth quarter and fiscal year ended May 28, 2022, in conjunction with the Company’s presentation at the LD Micro Invitational XII Investor Conference on June 8 at 2:30 P.M. PT / 5:30 P.M. ET. The presentation will be streamed live at https://ldinv12.mysequire.com/ and will also be posted on the Company’s investor relations website at https://www.rell.com/investor-relations. Preliminary fiscal year 2022 fourth quarter net sales are expected to be between $60.5 and $62.5 million, representing 19.9%-23.8% growth compared...

Continue reading

Vaccitech to Present at the Jefferies Healthcare Conference

Vaccitech to Present at the Jefferies Healthcare Conference

OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City. A live webcast of the presentation can be accessed through the Events section of the Vaccitech website. Following the live webcast, a replay will be available at the same location. About Vaccitech plcVaccitech (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development primarily of novel immunotherapies for the treatment...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.